MAY 19·Simply Wall StreetMed
Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?
AbCellera Biologics (ABCL) is showing a shift in its business model by advancing ABCL635, a nonhormonal menopause therapy, into Phase II clinical trials. This move signals a greater focus on internal clinical assets rather than solely relying on its drug discovery platform. While the company still faces ongoing losses and relies on uncertain partner income, the promising Phase I safety data and strong target engagement for ABCL635 could be a key catalyst for its future valuation.